Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3\6XmZ2dmO2aX;uJGF{e2G7 M{XKS|AvPcLizszN MkOxNlQhcA>? M3zsfpdifGW{ NGXWNIZud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? Mo\INlUyOjNyOEK=
Eca109 NUjKWHlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLGZVMxNjVxMj61M|Uh|ryP MVOyOE81QC95MjDo M4TvPJdifGW{ MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MmnqNlUyOjNyOEK=
Eca109 M2C5dmZ2dmO2aX;uJGF{e2G7 MV2wMlXDqM7:TR?= NGHjUYo3NzF{L{K0JIg> M4fhU5difGW{ NH64c3NqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg M2TMcFI2OTJ|MEiy
Eca109 NF;VRYZHfW6ldHnvckBCe3OjeR?= M333cFAvPcLizszN M37HTFI1KGh? NFi1N2p4[XSnch?= NWTkTIczcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NXj1UXc{OjVzMkOwPFI>
Eca109 NFLNN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMlXDqM7:TR?= M17VPVI1KGh? M2LzZZdifGW{ NIWwS2lqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm M{DhSlI2OTJ|MEiy
Eca109 NHHVSXlHfW6ldHnvckBCe3OjeR?= NFvTe|AxNjVxMTFOwG0> M{HSfVI1KGh? M3vNdJdifGW{ NVriVm1p\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= NXHtc49iOjVzMkOwPFI>
SW1116  NWjrenhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\jV4FzOC53L{GvNk82KM7:TR?= NVmwfIxmPDhiaB?= MX3EUXNQ NYP3OWNN\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MoP1NlQ5PzR{OE[=
LOVO NGXTNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HxTVAvPS9zL{KvOUDPxE1? MVq0PEBp NWPkfmpZTE2VTx?= NETEc5BmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v M{j3cFI1QDd2Mki2
SW1116  M{e3fGZ2dmO2aX;uJGF{e2G7 NEK0TFEyOCEQvF2= MXW0PEBp NX\pS|B5TE2VTx?= MnTTbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj NEPnVY0zPDh5NEK4Oi=>
LOVO M4L6d2Z2dmO2aX;uJGF{e2G7 MnTYNVAh|ryP M3TVblQ5KGh? M324SGROW09? NYntd2h1cW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M4TEZlI1QDd2Mki2
SW1116  MkXORZBweHSxc3nzJGF{e2G7 NHy4WHcyOCEQvF2= MYK0PEBp NFHQ[opFVVOR MkKy[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MoG4NlQ5PzR{OE[=
LOVO MkPNRZBweHSxc3nzJGF{e2G7 MXOxNEDPxE1? NED3PYc1QCCq MnTFSG1UVw>? NUj2ZWhl\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MV6yOFg4PDJ6Nh?=
RPMI-8226 Mn7QRZBweHSxc3nzJGF{e2G7 MVGxM|Ih|ryP NH;Lfpo1QC95Mj:5OkBp NUXPd3Q4TE2VTx?= NF;wc25qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF76c|IzPDh|M{GwPC=>
OPM-2  M{PGSmFxd3C2b4Ppd{BCe3OjeR?= MVexM|Ih|ryP M2HJdFczNzl4L{GyNEBp NUXSbIppTE2VTx?= NGfhcWpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4PtVlI1QDN|MUC4
JJN3  NYPVZlJlSXCxcITvd4l{KEG|c3H5 MY[wMlUwOSEQvF2= MYSyOE81QCCq NVj2UHNmTE2VTx?= NEnNU3JqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Ml;zNlQ5OzNzMEi=
NCI-H929  NHzFNZFCeG:ydH;zbZMhSXO|YYm= NVqwb|Y4OS9{IN88US=> M4rSeFczNzl4L{GyNEBp MlT2SG1UVw>? MkDKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHfEUlYzPDh|M{GwPC=>
RPMI-8226 NGG4em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHewNlgyNzJizszN MUGyOE81QC95MjDo MkLXSG1UVw>? NHS5bHNi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NX;INohQOjR6M{OxNFg>
OPM-2  NFTtc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfOTI1JOS9{IN88US=> MVSyOE81QC95MjDo M4ToTWROW09? M4[yeIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M1\WU|I1QDN|MUC4
JJN3  NIXzNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;hV2YxNjVxMTFOwG0> M4G3VFI1NzR6L{eyJIg> M{fvbWROW09? NYPtUWgx[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NVjIWlNTOjR6M{OxNFg>
NCI-H929  MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DifFEwOiEQvF2= MVqyOE81QC95MjDo NGDrbGZFVVOR NG\xSZNi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NXnYZ|dMOjR6M{OxNFg>
HeLa NYjRO4dNU2mwYYPlJGF{e2G7 M1WyRmtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> M3\vOVI1PzhyMEm4
HeLa M{PQc2tqdmG|ZTDBd5NigQ>? M2PQfmtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> M4fkZ|I1PzhyMEm4
HeLa NWX1[214U2mwYYPlJGF{e2G7 Mk\6T4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> Mn;6NlQ4QDByOUi=
HeLa M{fV[2tqdmG|ZTDBd5NigQ>? MlfoT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> M3uzcVI1PzhyMEm4
NB4 MnL6SpVv[3Srb36gRZN{[Xl? NULMU2d7Oi53L{WvO{42NzFyIN88US=> M1jDdVI1KGh? NWjjXGc2TE2VTx?= NEHzOGVqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi MWmyOFQ5PDh5MB?=
CD4+ CD25− T  MmWxSpVv[3Srb36gRZN{[Xl? NY\PUXppOS93IN88US=> NWDwWFhPemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w NYC5[I1[OjR2N{[zOlA>
BV-173 M1PHRmFxd3C2b4Ppd{BCe3OjeR?= MkexNE4zPS9yLkWvNE44PS9zIN88US=> M4DyUVQ5Nzd{L{m2JIg> M{\vRuKhWEKV MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MV:yOFQzOzZzMx?=
ML-1 NFT6THRCeG:ydH;zbZMhSXO|YYm= MlzVNE4zPS9yLkWvNE44PS9zIN88US=> MoPlOFgwPzJxOU[gbC=> MnLlxsBRSlN? NEnRfWFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MkLaNlQ1OjN4MUO=
HL-60 NGn6bWZCeG:ydH;zbZMhSXO|YYm= MV2wMlI2NzBwNT:wMlc2NzFizszN NHjMSm41QC95Mj:5OkBp M2PmfeKhWEKV NX:1bHlIcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NFTCbnYzPDR{M{[xNy=>
KG-1a MoHURZBweHSxc3nzJGF{e2G7 NWXDNohnOC5{NT:wMlUwOC55NT:xJO69VQ>? NFvPbmo1QC95Mj:5OkBp MVdCpHBDWw>? NVTl[pMxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M1q3OVI1PDJ|NkGz
BV-173 Mlv5SpVv[3Srb36gRZN{[Xl? NX\afnRiOjVyL{WwNI5O MWK0PEBp MkjtxsBRSlN? NFvJenRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M{XVdlI1PDJ|NkGz
CEM NF;5ZotHfW6ldHnvckBCe3OjeR?= MXKyOVAwPTBybl2= M3exWlQ5KGh? M4DwTeKhWEKV M2W1WIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MlvENlQ1OjN4MUO=
HL-60 NWLIV2pxTnWwY4Tpc44hSXO|YYm= NW\DNWxKOjVyL{WwNI5O Mm\ZOFghcA>? M2HJd:KhWEKV M3LtTIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NHPYNo4zPDR{M{[xNy=>
ML-1 M4j3TWZ2dmO2aX;uJGF{e2G7 NGXnPJgzPTBxNUCwcm0> MmHvOFghcA>? MonTxsBRSlN? MUXpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MnrTNlQ1OjN4MUO=
DLD-1 NUDzZ4NKTnWwY4Tpc44hSXO|YYm= MVyyOVAwPTBybl2= MUC0PEBp MXZCpHBDWw>? NFnPR5pldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MUeyOFQzOzZzMx?=
HCT-116 MW\GeY5kfGmxbjDBd5NigQ>? NIDBfG8zPTBxNUCwcm0> MmfROFghcA>? Mnm3xsBRSlN? M{Du[IRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M2HRWlI1PDJ|NkGz
U937-A/E-9/14/18  MkfHRZBweHSxc3nzJGF{e2G7 NFryUGYxNjBzL{CuNU8yNzFyIN88US=> MmPnOFghcA>? MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXrzbJJKOjR|MEC0OVY>
HT29 M2P3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP0[GJxPzJiaB?= NWfp[ohDUUN3ME2xOFAxyrFzN{mg{txO M4D2[VI1OTd{ME[x
SW48 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzwO|IhcA>? NHnCTYVKSzVyPUG1MlLDuTZwMjFOwG0> MlPpNlQyPzJyNkG=
HCT116 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTRO|IhcA>? M4nHVmlEPTB;MT63xtExNjRizszN NFL2WY4zPDF5MkC2NS=>
HepG2 MUfGeY5kfGmxbjDBd5NigQ>? MYOwMlUwOSEQvF2= MXGyOEBp M2jtXWROW09? NFf6ZnN2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M3PTfVI1OTR4OEe0
LS174T MUTGeY5kfGmxbjDBd5NigQ>? MVGwMlUwOSEQvF2= MWeyOEBp MUTEUXNQ NED1fWNt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> MWqyOFE1Pjh5NB?=
HepG2 M{LSXmFxd3C2b4Ppd{BCe3OjeR?= MlH6NU8yOC9zMECg{txO NF\aZXM4KGR? NYHjSGxiTE2VTx?= NXPYT3k5cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn3DNlQyPDZ6N{S=
LS174T Mn3oRZBweHSxc3nzJGF{e2G7 M4\hblEwOTBxMUCwJO69VQ>? MoXOO{Bl NYDQeVM1TE2VTx?= NEPu[WRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVSyOFE1Pjh5NB?=
QBC-939 NEjxcVNCeG:ydH;zbZMhSXO|YYm= M{HtdVEwOTBxMUCwJO69VQ>? MV[3JIQ> MVPEUXNQ NFfmNoRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFzVUmEzPDF2Nki3OC=>
U251 NXP6[Wp7SXCxcITvd4l{KEG|c3H5 NHy3ZYgyNzFyL{GwNEDPxE1? NHz4UJk4KGR? MULEUXNQ MmrvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHHBVXczPDF2Nki3OC=>
HL-60 M2XLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS5NIdTOSEQvF2= MmjxOFghcA>? NWLoR3BtcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= NXz0fXRjOjRyMECzNlQ>
MDA‑MB‑453 MV\GeY5kfGmxbjDBd5NigQ>? NV\Fd4NROC5{L{Gg{txO MV23NkBp NF;kNmZk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MmXuNlM5PDR{Mki=
HCC1569 NVjzbmlRTnWwY4Tpc44hSXO|YYm= MXqwMlIwOSEQvF2= MoHVO|IhcA>? MlO3Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NUi5XnVWOjN6NESyNlg>
BT‑474 NWjROVdvTnWwY4Tpc44hSXO|YYm= NW\jTYZwOC5{L{Gg{txO NX:2UI15PzJiaB?= NW\q[Gxo[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NWrCNYZWOjN6NESyNlg>
AGS NIrpemJCeG:ydH;zbZMhSXO|YYm= M1njOlUwOTBxMkCvOVAh|ryP NX;QXWJjPDkEoHlCpC=> M2H2RmROW09? NXP3SIFXcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NWntc3JjOjN3OEK3PFQ>
A549 NH\vO|VCeG:ydH;zbZMhSXO|YYm= NHOzdIg2NzFyL{KwM|UxKM7:TR?= M2SxTlQ5yqCqwrC= M33kUGROW09? MV7pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> M4PTXFI{PTh{N{i0
AGS  NEPGeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj0R5lGPS9zMD:yNE82OCEQvF2= NFe5WGw1QMLiaNMg M1jrS2ROW09? NWXsb4d2cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh MUmyN|U5Ojd6NB?=
Kasumi-1 M{PMemFxd3C2b4Ppd{BCe3OjeR?= MnX5NE42KM7:TR?= NWL1THdSPDkEoHlCpC=> NEO5TVJl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MkKyNlM1QTN|NEi=
OCI-AML3 MYLBdI9xfG:|aYOgRZN{[Xl? MWmyMlUh|ryP NIW2dng1QMLiaNMg NF\lPYNl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NHrndZEzOzR7M{O0PC=>
MV4-11 NUOwZ|NuSXCxcITvd4l{KEG|c3H5 M4P2WlIvPSEQvF2= MV60POKhcMLi NUS2e4h2\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NVnJc2tFOjN2OUOzOFg>
NK  NFvuTZhEgXSxdH;4bZR6KEG|c3H5 MlvXNE4xOi1{MDFOwG0> NVjGT|drPSCm M{TFOYRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? MljVNlM{OjhyOEi=
NK  M1TpUmFxd3C2b4Ppd{BCe3OjeR?= M3;oXFAvODJvMkCg{txO NGDB[4s2KGR? NE\PU5pl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NHTLS5IzOzN{OEC4PC=>
NK  MkXjSpVv[3Srb36gRZN{[Xl? NHzwdm4xNjBzLUKwJO69VQ>? MkHrOUBl MYHjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NEf5UmgzOzN{OEC4PC=>
MOLT4/DNR MVnGeY5kfGmxbjDBd5NigQ>? MXG1JO69VQ>? M3O4[|Qh\A>? Mn3ndoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NUPmSGhLOjNyNkC1O|A>
Jurkat/DOX NYPrO|drTnWwY4Tpc44hSXO|YYm= MlnnOUDPxE1? MoTQOEBl M1XjXJJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v M4e1SlI{ODZyNUew
MOLT4/DNR NH7rOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCeVUh|ryP NUDjR4hlPCCm MVry[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NELqfGIzOzB4MEW3NC=>
Jurkat/DOX NX\wNYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC1JO69VQ>? MVu0JIQ> MV\y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MY[yN|A3ODV5MB?=
ccRCC  NIjVPGFCeG:ydH;zbZMhSXO|YYm= MkjMNE4xOS1zMN88US=> NW\s[2h7PzJiaB?= NITs[YVFVVOR MWroZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NIjRTHUzOjh{NkS2Oy=>
TNBC  NW\RPFduSXCxcITvd4l{KEG|c3H5 NH7rdnUxNjBzLUGw{txO MXm3NkBp NXSzXoRDTE2VTx?= MV7oZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v Mnz0NlI5OjZ2Nke=
A498 MWnBdI9xfG:|aYOgRZN{[Xl? MXWwMlAyNTFyzszN Mo\SO|IhcA>? NGfxUIhFVVOR MnTNbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M{ixWVIzQDJ4NE[3
KIJ265T Mk[2RZBweHSxc3nzJGF{e2G7 M3HOZVAvODFvMUFOwG0> NGrFR444OiCq MUPEUXNQ M2HSbYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> Mmj6NlI5OjZ2Nke=
MDA-231 Mk[5RZBweHSxc3nzJGF{e2G7 MW[wMlAyNTFyzszN MnzKO|IhcA>? NVzIeZhETE2VTx?= NGDH[XpqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NV[5PJhXOjJ6Mk[0Olc>
BT-20 MofmRZBweHSxc3nzJGF{e2G7 MWOwMlAyNTFyzszN MkTKO|IhcA>? MXXEUXNQ MVjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NUjpcpl3OjJ6Mk[0Olc>
U937 M17yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHuUokyPS1{MDFOwG0> MkLPNlQwPDhxN{KgbC=> MXrpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NGLPSngzOjd4N{CyNS=>
HL60 NEDwfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\OOU0zOCEQvF2= MkmxNlQwPDhxN{KgbC=> NUTKUI46cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NFvsUmozOjd4N{CyNS=>
U937 M2XPU2Fxd3C2b4Ppd{BCe3OjeR?= MorqNVUh|ryP NYnSfo1TOjRxNEivO|IhcA>? MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4XOWlIzPzZ5MEKx
HL60 MUnBdI9xfG:|aYOgRZN{[Xl? MWSxOUDPxE1? MUOyOE81QC95MjDo M3fqTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NG\kdnczOjd4N{CyNS=>
LS411N  M17wcmFxd3C2b4Ppd{BCe3OjeR?= NEK4e3QxNjVizszN MorSO|IhcA>? NFe3dlBqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= MoTSNlI1PjF4OUW=
MDA-MB-231 M4fWfGFxd3C2b4Ppd{BCe3OjeR?= MlTiNVAh|ryP MnP1OFghcA>? MV;y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVHH[lZDOjF6OEe2PVc>
MCF-7  NG[wfWhCeG:ydH;zbZMhSXO|YYm= Mk[0NVAh|ryP NIfaSHY1QCCq MVTy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3HE[lIyQDh5Nkm3
A375 NEDBN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlUh|ryP M1jkUlEwPS96IHS= MkL4bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MoTjNlE4QTZ4MkK=
SKMEL1 NVHjeZRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPzNE42KM7:TR?= M13jSFEwPS96IHS= NYTBUGd{cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NYjnR3ZMOjF5OU[2NlI>
SKMEL3 NYfodZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jPWVAvPSEQvF2= M4T4WFEwPS96IHS= M37zVIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mn3sNlE4QTZ4MkK=
SKMEL28 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrLNWExNjVizszN MX[xM|UwQCCm NG[1WGNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M4rEdFIyPzl4NkKy
MeWo MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK2eYxUOC53IN88US=> M4jxOVEwPS96IHS= MoLkbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MlG4NlE4QTZ4MkK=
B16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMlUh|ryP Mmi4NU82NzhiZB?= MXzpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NVvHW3JlOjF5OU[2NlI>
Ly 1 M4HneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HnTFI1KGh? MYLJR|UxRTdwMzFOwG0> NHfQZ3QzOTd5MkC0PS=>
Ly 7 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjkUo0zPCCq NH\pXmRKSzVyPUGwMlch|ryP M{PHS|IyPzd{MES5
Su-DHL6 NEPIUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPLbHQzPCCq MnPBTWM2OO,:nkKwJO69VQ>? MXGyNVc4OjB2OR?=
Ly 10 M3rDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDlTHg3OjRiaB?= MUTJR|Ux97zgMkCg{txO M{\s[FIyPzd{MES5
RIVA NUnmTFN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOEBp NX;pNIRQUUN3MP-8olIxKM7:TR?= MkfJNlE4PzJyNEm=
Su-DHL2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX3U48zPCCq MkPsTWM2OO,:nkKwJO69VQ>? M2\BVlIyPzd{MES5
Ly 1 NHTRcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0PEBp NVG5S44zUUN3ME2wMlM1KM7:TR?= M3n0XlIyPzd{MES5
Ly 7 NVGxOW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfVOFghcA>? NI\qTo5KSzVyPUCuNFI2KM7:TR?= NEXDTWgzOTd5MkC0PS=>
Su-DHL6 NFnZeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe0PEBp NVm5TW02UUN3MP-8olIxKM7:TR?= NX3sOGN5OjF5N{KwOFk>
Ly 10 M1rEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHjNmY2PDhiaB?= Mn\sTWM2OD1zLkig{txO Mkf4NlE4PzJyNEm=
RIVA NEnoT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Htd|Q5KGh? MVXJR|Ux97zgMkCg{txO MnnQNlE4PzJyNEm=
Su-DHL2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1UYg1QCCq MVnJR|UxRTF5LkSg{txO NYD2XYNHOjF5N{KwOFk>
Ly 1 NVK5NotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjNVow4OiCq Mki5TWM2OD1yLkCxJO69VQ>? M{LqZlIyPzd{MES5
Ly 7 M1HSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LpcVczKGh? NF;iZpBKSzVyPUCuNFE5KM7:TR?= NFz3bYMzOTd5MkC0PS=>
Su-DHL6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm3NkBp M136Z2lEPTB;MT62JO69VQ>? NGnT[|czOTd5MkC0PS=>
Ly 10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7hc5Z{PzJiaB?= NY\6[W1kUUN3ME2xMlIh|ryP MV2yNVc4OjB2OR?=
RIVA NGq0[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;RfFczKGh? Ml\GTWM2OO,:nkKwJO69VQ>? MkPpNlE4PzJyNEm=
Su-DHL2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp NEnhPJVKSzVyPUGxMlIh|ryP MoDINlE4PzJyNEm=

... Click to View More Cell Line Experimental Data
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4
CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03017131 Recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT03021395 Recruiting AML Institute of Hematology & Blood Diseases Hospital February 8 2017 Phase 1|Phase 2
NCT03226418 Recruiting Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia University of Nebraska|National Cancer Institute (NCI) July 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02203773 Active not recruiting Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML AbbVie|Genentech Inc. July 7 2015 Phase 1|Phase 2
NCT03066648 Recruiting Leukemia|Leukemia Myeloid|Leukemia Myeloid Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases Novartis Pharmaceuticals|Novartis July 6 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

selleck catalog

DNA Methyltransferase Signaling Pathway Map
Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID